Знаков). was a striking absence of serologic signs of lupus, however, and the rash resolved after spironolactone (the active ingredient contained in Aldactone) was

was a striking absence of serologic signs of lupus, however, and the rash resolved after spironolactone (the active ingredient contained in Aldactone) was discontinued.[Ref]

Dermatologic side effects have occurred in less than 5% of patients, and included rare cases of lichen planus and a lupus-like syndrome. Postmarketing dermatologic side effects have included Stevens-Johnson Syndrome, toxic epidermal necrolysis, drug rash with eosinophilia and systemic symptoms (DRESS), alopecia, and pruritus.[Ref]

Hypersensitivity

A 44-year-old woman developed acute pulmonary edema, disseminated intravascular coagulation, and a generalized rash within 30 minutes of ingesting a single spironolactone-hydrochlorothiazide tablet. An inadvertent rechallenge resulted in the same sequelae.[Ref]

Hypersensitivity side effects have included rashes which occurred in about 1% of patients. Rare cases of eosinophilia, contact dermatitis and anaphylaxis have been reported.[Ref]

Gastrointestinal

Gastrointestinal side effects have been minor. General abdominal discomfort, diarrhea, and vomiting were reported in less than 5% of patients. However, a case-controlled study has revealed that patients receiving spironolactone (the active ingredient contained in Aldactone) are at an increased risk (dose-related) of developing upper gastrointestinal adverse events such as gastric bleeding and gastric or duodenal ulcers.[Ref]

Hematologic

Hematologic side effects have been rare, and included case reports of reversible leukopenia and agranulocytosis.[Ref]

Some cases of agranulocytosis are associated with a normal bone marrow, suggesting peripheral destruction of white blood cells, while some cases of agranulocytosis have been associated with bone marrow hypocellularity of the myelocytic cell lines.[Ref]

Hepatic

Hepatic side effects have been rare. Two cases of hepatitis have been strongly associated with spironolactone (the active ingredient contained in Aldactone) [Ref]

A 53-year-old woman with aldosteronism secondary to an adrenal adenoma developed reversible hepatitis during spironolactone therapy. The syndrome resolved upon drug discontinuation, and was reproducible on rechallenge. The authors did not find signs or symptoms of hypersensitivity to the drug.